Global Pruritus Therapeutics Market - 2022-2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	200 Pages	DataM Intelligence 4Market Research LLP	October, 2022	DTAM17448062

Best Price Guarantee
Price	from $4,350
Length	200 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	October, 2022
SKU	DTAM17448062

Global Pruritus Therapeutics Market - 2022-2029

Market Overview

Pruritus Therapeutics Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 6.1% during the forecast period (2022-2029).

Pruritus, or itch, is commonly associated with primary skin disorders such as atopic dermatitis, urticaria, psoriasis, Masto cytosis, and dermatitis herpetiformis, among others. A typical itching generally forms the diagnosis of a major dermatologic disorder. Several skin diseases related to pruritus, such as renal pruritus, hematologic pruritus, cholestatic pruritus, idiopathic generalized pruritus, pruritus related to malignancy and endocrine pruritus. Increased ions such as calcium, phosphate, and magnesium are found in pruritic patients' skin. Severe pruritus leads to scratching that causes secondary skin problems such as eczematisation, dryness, infection, excoriation, Contact allergy, and lichenification.

Market Dynamics

The global pruritus therapeutics market is growing due to several factors, such as the increasing incidence of dermatological disorders influencing the occurrence of pruritus and the growing demand for proper diagnostics and therapeutics to treat such medical conditions. The development of new therapeutics for pruritus is forcing global market growth.

The development of new targeted therapies for different pruritus is driving the growth of the global pruritus therapeutics market. For instance, the development of Duplimab, which is a monoclonal antibody that specifically targets interleukin-4 receptors that are involved in the progression of the inflammatory response with these other novel therapeutics, for example, Crisaborole 2% ointment and others are in the pipeline of major key market players for topical medication including the Janus kinase inhibitors. Furthermore, the approval of these newly developed therapeutics by different regulatory bodies propels the market towards growth. For instance, in June 2022, Dupixent (Duplimab), developed by Sanofi, is the first biologics medicine validated by the United States Food and Drug Administration to treat moderate to severe dermatitis in children aged 6 months to 5 years. These market events and the development of new therapeutics are fueling the market growth globally.

The lack of awareness and incidences of drug side effects will become a hurdle in the pruritus therapeutics market growth.

However, the lack of awareness towards therapeutics for pruritus and the associated side effects associated with pruritus therapeutics hinder the market's growth.

Industry analysis.

The pruritus therapeutics market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory analysis, pricing analysis and pipeline analysis, Etc.

COVID-19 Impact Analysis

The American Contact Dermatitis Society informed that the covid-19 pandemic had increased the number of contact dermatitis cases. Amidst covid-19, the CDC recommended repetitive hand hygiene with soaps, detergents, and hand sanitization through alcohol-containing hand sanitizers, which lead to the integrity and integrity function alteration in the skin barrier, raising the risk of dermatitis. Also, during the covid-19 outbreak, healthcare professionals were suggested to employ personal protective kits, which have caused a rise in the number of healthcare professionals experiencing contact dermatitis, positively impacting the pruritus therapeutics market.

Segment Analysis/B>

The corticosteroids will dominate the pruritus therapeutics market during the forecast period (2022-2029).

The corticosteroids segment accounted for the highest market share in 2021 and is expected to dominate the Pruritus therapeutics market during the forecast period (2022-2029) since corticosteroids are widely used as the first line of treatment for acute pruritus associated with moderate to severe inflammatory skin diseases, such as AD, allergic contact dermatitis, psoriasis and lichen planus. Corticosteroids are activated glucocorticoid receptors that inhibit cytokine activation, thereby decreasing local inflammation and indirectly controlling pruritus. More than 30 different topical steroid formulations are available in the United States, and these are prepared on different bases (e.g., solution, lotion, cream or ointment). Topical corticosteroids range in potency from low (Class VII) to high or ultra-potent (Class I). It is generally accepted that the clinical efficacy to treat inflammation, and indirectly pruritus, correlates with steroid potency.

Geographical Analysis

North America is subjugating the pruritus therapeutics market.

North America dominated the pruritus therapeutics market in 2021. It is estimated that North America will command the global pruritus therapeutics market during the forecast period (2022-2029) since most key market players are headquartered in North America and are involved in developing new drug therapies such as biologics. Examples are Bausch Health, Astellas Pharma U.S.Inc., Pfizer Inc., Mylan, Bayer AG, Allergen, Eli Lilly, and many more. Also, owing to the health care sector developments, organizations and societies are actively looking out for pruritus and government initiatives for spreading awareness about pruritus. For instance, founded in 1989, the American Contact Dermatitis Society is focused on pruritus with over 2,500 healthcare professionals in the field of pruritus and related skin inflammatory diseases. Also, the North American Contact Dermatitis Group is helping thousands of people make informed, evidence-based skin care decisions. These facts show that the North American region will dominate the pruritus therapeutics market over the forecast period.

Competitive Landscape

The pruritus therapeutics market is competitive, with few major players competing to gain market share. Some major players in the global pruritus therapeutics market include Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, Teva Pharmaceutical Industries Ltd, Pfizer, Sanofi, GlaxoSmithKline, Merck, among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the global Pruritus Therapeutics market's growth. For instance, in January 2022, Pfizer acquired U.S.FDA approval for its Cibinqo (Adrocitinib), an oral once-a-day Janus kinase inhibitor for treating adults suffering from dermatitis. Also, in April 2022, Leo Pharma presented its interim long-term efficacy data for Adbry (Tralokinumab-ldrm). Such incidences create a competitive environment in the Pruritus Therapeutics market.

Leo Pharma

Overview

Leo Pharma is a leading company in the dermatology market, founded in 1908 and headquartered in Denmark. It is primarily focused on research and development to advance the science of dermatology.

Product Portfolio

Leo Pharma’s dermatological product portfolio has Adtralza, Dovobet, Dovonex, Enstilar, Finacea, Kyntheum, Protopic, Skinoren, Fucidin, and Fucibet.

The global pruritus therapeutics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

1. Methodology and Scope: 1.1. Research Methodology; 1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics: 4.1. Market Impacting Factors; 4.1.1. Drivers; 4.1.1.1. Research and Development; 4.1.1.2. Increased Awareness; 4.1.1.3. Market Strategies; 4.1.2. Restraints; 4.1.2.1. Treatment Side Effects; 4.1.2.2. Stringent Regulatory Bodies; 4.1.3. Opportunity; 4.1.4. Impact Analysis
5. Industry Analysis: 5.1. Porter's Five Forces Analysis; 5.2. Epidemiological Analysis; 5.3. Research and Developments; 5.4. Pipeline Analysis; 5.5. Supply Chain Analysis; 5.6. Regulatory Analysis
6. COVID-19 Analysis: 6.1. Analysis of Covid-19 on the Market; 6.1.1. Before COVID-19 Market Scenario; 6.1.2. Present COVID-19 Market Scenario; 6.1.3. After COVID-19 or Future Scenario; 6.2. Pricing Dynamics Amid Covid-19; 6.3. Demand-Supply Spectrum; 6.4. Government Initiatives Related to the Market During Pandemic; 6.5. Manufacturer’s Strategic Initiatives; 6.6. Conclusion
7. By Disease Type: 7.1. Introduction; 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment; 7.1.2. Market Attractiveness Index, By Disease Type Segment; 7.2. Atopic Dermatitis; 7.2.1. Introduction; 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029; 7.3. Allergic Contact Dermatitis; 7.4. Urticaria; 7.5. Others
8. By Route of Administration: 8.1. Introduction; 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment; 8.1.2. Market Attractiveness Index, By Route of Administration Segment; 8.2. Oral; 8.2.1. Introduction; 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029; 8.3. Injectables; 8.4. Topical
9. By Drug Class: 9.1.1. Introduction; 9.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment; 9.1.3. Market Attractiveness Index, By Drug Class Segment; 9.1.4. Antihistaminic; 9.1.5. Introduction; 9.1.6. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029; 9.2. Corticosteroids; 9.3. Counterirritants; 9.4. Local Anesthetics; 9.5. Calcineurin Inhibitors; 9.6. Immunosuppressant; 9.7. Others
10. By Distribution Channel: 10.1. Introduction; 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment; 10.1.2. Market Attractiveness Index, By Distribution Channel Segment; 10.2. Hospital Pharmacy; 10.2.1. Introduction; 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029; 10.3. Retail Pharmacy; 10.4. Online Pharmacy
11. By Region: 11.1. Introduction; 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region; 11.1.2. Market Attractiveness Index, By Region; 11.2. North America; 11.2.1. Introduction; 11.2.2. Key Region-Specific Dynamics; 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type; 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration; 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class; 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel; 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country; 11.2.7.1. The U.S.; 11.2.7.2. Canada; 11.2.7.3. Mexico; 11.3. Europe; 11.3.1. Introduction; 11.3.2. Key Region-Specific Dynamics; 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type; 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration; 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class; 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel; 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country; 11.3.7.1. Germany; 11.3.7.2. The U.K.; 11.3.7.3. France; 11.3.7.4. Italy; 11.3.7.5. Spain; 11.3.7.6. Rest of Europe; 11.4. South America; 11.4.1. Introduction; 11.4.2. Key Region-Specific Dynamics; 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type; 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration; 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class; 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel; 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country; 11.4.7.1. Brazil; 11.4.7.2. Argentina; 11.4.7.3. Rest of South America; 11.5. Asia Pacific; 11.5.1. Introduction; 11.5.2. Key Region-Specific Dynamics; 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type; 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration; 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class; 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel; 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country; 11.5.7.1. China; 11.5.7.2. India; 11.5.7.3. Japan; 11.5.7.4. Australia; 11.5.7.5. Rest of Asia Pacific; 11.6. Middle East and Africa; 11.6.1. Introduction; 11.6.2. Key Region-Specific Dynamics; 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type; 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration; 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class; 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape: 12.1. Key Developments and Strategies; 12.2. Company Share Analysis; 12.3. Product Benchmarking
13. Company Profiles: 13.1. Leo Pharma; 13.1.1. Company Overview; 13.1.2. Product Portfolio and Description; 13.1.3. Key Highlights; 13.1.4. Financial Overview; 13.2. Bausch Health; 13.3. Astellas Pharma U.S.Inc.; 13.4. Pfizer Inc.; 13.5. Mylan; 13.6. Bayer AG; 13.7. Allergen; 13.8. Sanofi; 13.9. Eli Lilly; 13.10. Sandoz Inc.; LIST NOT EXHAUSTIVE
14. DataM: 14.1. Appendix; 14.2. About Us and Services; 14.3. Contact